An Advanced Practitioner's Guide to Cell Signaling Pathways in Non-Small Cell Lung Cancer

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by educational grants from Genentech and Merck Sharp & Dohme Corp.

Release date: November 21, 2017
Expiration date: November 21, 2018
Estimated time to complete activity: 1.0 hour

Faculty

Moderator:
Elizabeth Waxman, RN, MSN, NP-C, AOCN
The University of Texas MD Anderson Cancer Center

Panel:
Whitney Lewis, PharmD, BCOP
The University of Texas MD Anderson Cancer Center

Melinda Oliver, BA,BSN, RN, MPAP
The University of Texas MD Anderson Cancer Center

Frank Mott, MD, FACP
The University of Texas MD Anderson Cancer Center

Activity Rationale and Purpose
Lung cancer is the leading cause of cancer-associated mortality, with 224,390 new cases and 158,080 deaths estimated in 2016 (United States). Lung cancer is histologically divided into small cell lung cancer and NSCLC, which occur in 15% and 85% of lung cancer cases, respectively. The majority of patients present with advanced disease at diagnosis; prognosis is poor, and the 5-year survival rate is 4%, with frequent metastases to bone, liver, and brain. Late diagnosis is a fundamental obstacle to improving outcomes in lung cancer, exacerbating the unmet medical need for APs to maintain a continually high educational status about increasingly complex diagnostics and treatment options for the management of advanced/metastatic NSCLC. This activity will provide education to assist APs in closing or narrowing this medical gap, providing a better understanding of the use of targeted and immunotherapies as they apply to the management of NSCLC.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:

  • Demonstrate an increased understanding of the mechanisms of action of targeted and immunotherapies in the treatment of NSCLC
  • Discuss the range of genetic variants in NSCLC and how these are used to select targeted agents for patients with NSCLC
  • Interpret a patient’s therapeutic response to immunotherapies to help ensure an optimized outcome
  • Identify current diagnosis and treatment paradigms for patients with squamous cell NSCLC
  • Identify and manage adverse events that occur with the use of immunotherapies across all subtypes of NSCLC

Continuing Education

Physicians

The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

https://education.annenberg.net/sites/education.annenberg.net/files/Provider-Logo-BW-jpg-.jpg

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hours may be earned for successful completion of this activity.

Pharmacists

This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-17-100-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty
Ms. Waxman has nothing to disclose.
Ms. Oliver has nothing to disclose.
Dr. Lewis has nothing to disclose.
Dr. Mott has nothing to disclose.

Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Planners
Chris Cherry has nothing to disclose.

Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Moshe Ornstein, MD, MA, Cleveland Clinic, has nothing to disclose.

Kimberly D. Allman, CNP, Cleveland Clinic, has received consulting or honoraria fees from Exelixis, and has served on speakers’ bureaus for Exelixis, Pfizer, and Sanofi.

Annenberg Center for Health Sciences at Eisenhower
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

Statement of Credit: Participants who successfully complete this activity (including scoring 70% on the learning assessment and completing and submitting the evaluation form) will be able to download a statement of credit.

Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/21/2017
Course expires: 
11/20/2018
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Accreditation Period

Course opens: 
11/21/2017
Course expires: 
11/20/2018

Price

Cost:
$0.00
Please login or register to take this course.